exRNAdisease

General Information

Database ID:

exR0079048

RNA Name:

PLAGL2

RNA Type:

mRNA

Chromosome:

chr20

Starnd:

Coordinate:

Start Site(bp):

32192504

End Site(bp):

32207743

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ABCC4	chr13	95019835	95301475	-
ABLIM1	chr10	114431113	114768061	-
ADGRV1	chr5	90529344	91164437	+
AK4	chr1	65147549	65232145	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-214-3p	chr1	172138816	172138837	-
hsa-miR-185-5p	chr22	20033153	20033174	+
hsa-miR-302a-3p	chr4	112648186	112648208	-
hsa-miR-34c-5p	chr11	111513451	111513473	+
hsa-miR-302b-3p	chr4	112648489	112648511	-
hsa-miR-302c-3p	chr4	112648366	112648388	-
hsa-miR-302d-3p	chr4	112648006	112648028	-
hsa-miR-373-3p	chr19	53788748	53788770	+
hsa-miR-485-5p	chr14	101055427	101055448	+
hsa-miR-520e-3p	chr19	53675764	53675784	+
hsa-miR-520a-3p	chr19	53690933	53690954	+
hsa-miR-519b-3p	chr19	53695263	53695284	+
hsa-miR-520b-3p	chr19	53701267	53701287	+
hsa-miR-520c-3p	chr19	53707506	53707527	+
hsa-miR-520d-3p	chr19	53720149	53720170	+
hsa-miR-519a-3p	chr19	53762397	53762418	+
hsa-miR-873-5p	chr9	28888925	28888945	-
hsa-miR-1270	chr19	20399320	20399342	-
hsa-miR-302e	chr11	7234771	7234787	+
hsa-miR-1321	chrX	85835832	85835849	+

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC245014.3	chr1	145281116	145281462	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference